Company intelligence / Profile preview

Arkuda Therapeutics

Watertown, Massachusetts, United States

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Arkuda Therapeutics developed small molecule enhancers of lysosomal function which were acquired by Johnson & Johnson in January 2025. Their lead candidate ARKD-104 was in IND-enabling studies with plans to initiate first-in-human trials in the first half of 2024.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Granulins

Pre-clinical

Indications: Frontotemporal dementia, Alzheimer's disease, Parkinson's disease

Partnerships

Johnson & Johnson (option and asset purchase agreement)

Beyond the preview

Go deeper on Arkuda Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arkuda Therapeutics.

Explore the full profile